8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934


               Date of Earliest Event Reported: December 15, 2004



                               GELSTAT CORPORATION
             (Exact name of registrant as specified in its charter)



           Minnesota                   0-21394                41-1713474
  (State of other jurisdiction   (Commission File No.)      (IRS Employer
       of incorporation)                                Identification Number)


            1650 West 82nd Street, Suite 1040, Bloomington, MN 55431
               (Address of principal executive offices) (Zip Code)


       Registrant's telephone number, including area code: (952) 881-4105

              (Former name, former address and former fiscal year,
                         if changed since last report):


Item 8.01 Other Events

      Effective December 15, 2004, GelStat Corporation and DTLL, Inc. announced
the signing of a non-binding Letter of Agreement (LOA) whereby GelStat's wholly
owned subsidiary, GS Pharma, Inc., will receive 12,500,000 common stock shares
of DTLL, Inc. in return for the exclusive, worldwide license of all rights to
the development and commercialization of pharmaceutical (prescription drug)
preparations related to GelStat's intellectual property and ongoing research and
development work.

      Item 99.1 Exhibits


      Press Release dated December 15, 2004.


                                       2


                                   SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


Dated: December 15, 2004              GELSTAT CORPORATION


                                      By
                                        ----------------------------------------
                                        Stephen C. Roberts, Chief Executive
                                        Officer (Principal Executive Officer)
                                        and Authorized Signatory


                                       3

EX-99.1

Press Release:

GelStat Corporation and DTLL, Inc. Execute Letter of Agreement

Wednesday December 15, 9:29 am ET

Proposed Transaction Would Effectively Merge GelStat's Wholly Owned
Pharmaceutical Subsidiary with DTLL, Inc.

MINNEAPOLIS, Dec. 15 /PRNewswire-FirstCall/ -- GelStat Corporation (OTC Bulletin
Board: GSAC - News) and DTLL, Inc. (OTC Bulletin Board: DTLI - News) today
announced the signing of a non-binding Letter of Agreement (LOA) whereby
GelStat's wholly owned subsidiary, GS Pharma, Inc., will receive 12,500,000
common stock shares of DTLL, Inc. in return for the exclusive, worldwide license
of all rights to the development and commercialization of pharmaceutical
(prescription drug) preparations related to GelStat's intellectual property and
ongoing research and development work.

The proposed transaction, if completed, will effectively result in GelStat
Corporation owning approximately 94 percent of then issued and outstanding
shares of DTLL. The final closing of the transaction is expected by December 31,
2004.

As originally announced October 26, 2004, the GS Pharma subsidiary was formed to
provide a scientific and commercial focus for the development of pharmaceutical
opportunities.

"As previously stated, our goal with respect to these prescription
pharmaceutical opportunities has been to maximize shareholder value by promoting
their commercialization while retaining significant ownership interest, but
without the risk of further direct investment on the part of GelStat," said
Stephen Roberts, M.D. chairman and chief executive officer of GelStat. "I
believe the proposed transaction with DTLL represents the best interests of both
companies' shareholders and is a major step forward as we continue to execute
our long term goals."

About GelStat Corporation

GelStat Corporation is a consumer healthcare company dedicated to the
cost-effective development and marketing of advanced OTC health care products.
Development efforts are focused on very large markets where GelStat products can
offer improved efficacy, safety, and/or convenience over existing OTCs.

For more information, visit http://www.GelStat.com .

Forward-Looking Statements

This press release contains "forward-looking" statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Any statement other than a
statement of historical fact should be considered a forward- looking statement.
Such forward-looking statements are based on the Company's current expectations
and involve known and unknown risks, uncertainties, or other factors which may
cause actual results, performance or achievements of the Company to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Risks, uncertainties
and assumptions include the possibility that the market for the sale of certain
products, or all products, may not develop as expected, or at all. Readers are
cautioned not to place undue reliance on those forward- looking statements,
which speak only as of the date hereof. The company undertakes no obligation and
does not intend to release publicly any revisions to these forward-looking
statements to reflect events or circumstances after the date hereof or to
reflect unanticipated events or developments.